The 340B Showdown: HRSA Proceeds Towards Enforcement Despite Litigation
FDA Law Blog
SEPTEMBER 29, 2021
Despite the ongoing legal proceedings, HRSA sent letters to the drug companies on May 17, 2021 stating that their 340B restrictions violated the 340B statute and that they “must immediately begin offering its covered outpatient drugs at the 340B ceiling price to covered entities through their contract pharmacy arrangements.” Becerra , No.
Let's personalize your content